Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Scott_Liu
|
| gptkbp:collaboratesWith |
gptkb:AbbVie
gptkb:Jacobson_Pharma |
| gptkbp:country |
gptkb:China
|
| gptkbp:focus |
biosimilars
innovative biologics |
| gptkbp:founded |
2010
|
| gptkbp:headquarters_location |
gptkb:Shanghai
|
| gptkbp:industry |
biopharmaceuticals
|
| gptkbp:market |
global
|
| gptkbp:numberOfEmployees |
over 1,000
|
| gptkbp:parentCompany |
gptkb:Fosun_Pharma
|
| gptkbp:product |
gptkb:HLX01_(rituximab_biosimilar)
gptkb:HLX02_(trastuzumab_biosimilar) gptkb:HLX03_(adalimumab_biosimilar) gptkb:HLX04_(bevacizumab_biosimilar) |
| gptkbp:researchArea |
oncology
autoimmune diseases |
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
2019 |
| gptkbp:stockSymbol |
gptkb:2696.HK
|
| gptkbp:website |
https://www.henlius.com
|
| gptkbp:bfsParent |
gptkb:Zhangjiang
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shanghai Henlius Biotech
|